Malvern, PA, March 29, 2017 — PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with an initial focus on cardiopulmonary disorders, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at Needham & Company’s 16th Annual Healthcare Conference on Wednesday, April 5, at 11:40 a.m. EDT at The Westin New York Grand Central in New York City.

For additional information on the conference, please visit:

About PhaseBio

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with a focus on cardiopulmonary disorders. The company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less-frequent dosing and better patient compliance. PhaseBio’s lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit


Media Contact:
Laura Bagby, 6 Degrees
(312) 448-8098